Just got this in an email ...Thu, 30 Mar at 9:34 am
Thursday, 30 March 2023PLS - PILBARA MINERALS LIMITED
Citi rates PLS as Buy (1) - The board at Pilbara Minerals has approved the final investment decision for the P1000 project which is expected to produce 1000ktpa of spodumene concentrate.
Capex is around -$200m higher than the consensus forecast, which didn't surprise the analyst in the current inflationary environment.
The broker lowers its target to $4.60 from $4.80 though notes potential upside for realised pricing heading into the March quarter result. Buy.
Target price is $4.60 Current Price is $3.94 Difference: $0.66 If PLS meets the Citi target it will return approximately 17% (excluding dividends, fees and charges). Current consensus price target is $5.53, suggesting upside of 40.2%(ex-dividends)The company's fiscal year ends in June.
Forecast for FY23:
Citi forecasts a full year FY23 dividend of 24.00 cents and EPS of 80.30 cents . At the last closing share price the estimated dividend yield is 6.09%. At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 4.91. How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 85.5, implying annual growth of 350.5%. Current consensus DPS estimate is 27.2, implying a prospective dividend yield of 6.9%. Current consensus EPS estimate suggests the PER is 4.6.
Forecast for FY24:
Citi forecasts a full year FY24 dividend of 17.00 cents and EPS of 67.80 cents . At the last closing share price the estimated dividend yield is 4.31%. At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 5.81. How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 78.6, implying annual growth of -8.1%. Current consensus DPS estimate is 18.8, implying a prospective dividend yield of 4.8%. Current consensus EPS estimate suggests the PER is 5.0.
Market Sentiment: 0.8All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
- Forums
- ASX - By Stock
- PLS
- Good News & Bad News
Good News & Bad News, page-26509
-
- There are more pages in this discussion • 17,881 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PLS (ASX) to my watchlist
(20min delay)
|
|||||
Last
$3.02 |
Change
-0.040(1.31%) |
Mkt cap ! $9.210B |
Open | High | Low | Value | Volume |
$3.08 | $3.11 | $3.02 | $55.82M | 18.22M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
37 | 424619 | $3.02 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$3.03 | 17344 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
37 | 424619 | 3.020 |
26 | 559636 | 3.010 |
94 | 368279 | 3.000 |
16 | 98735 | 2.990 |
19 | 101042 | 2.980 |
Price($) | Vol. | No. |
---|---|---|
3.030 | 17344 | 2 |
3.040 | 82598 | 7 |
3.050 | 159743 | 8 |
3.060 | 150693 | 9 |
3.070 | 155606 | 10 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
PLS (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online